ARTV vs ZTS · $37.3M cap vs P/E 25, rev $2.47B
Artiva Biotherapeutics, Inc. Common Stock (ARTV) versus Zoetis Inc (ZTS) — a side-by-side from cached financials, not a winner call.
Artiva Biotherapeutics, Inc. Common Stock (ARTV) is a biotechnology company listed on US.
Zoetis Inc (ZTS) is a drug manufacturers - specialty & generic company listed on US.
Latest reported ARTV revenue for 2025-12-31 was $0. Net income was -$83.9M. Revenue was down 100.0% from 2024-12-31 to 2025-12-31. ARTV currently screens at market cap $37.3M.
Latest reported ZTS revenue for 2026-06-30 was $2.47B. Net income was $691.0M. Revenue was up 9.1% from 2026-03-31 to 2026-06-30. ZTS currently screens at market cap $64.65B and trailing P/E 24.9.
ARTV currently screens at market cap $37.3M. ZTS currently screens at market cap $64.65B and trailing P/E 24.9.
Not investment advice. Open the ARTV and ZTS stock pages for the full models.
Not investment advice.